They provide additional evidence for the hypothesis that PMCA4b functions as a signaling molecule, and given that PMCA4b modulates the development of cardiac hypertrophy, its interaction with renalase may have particular clinical relevance for patients with hypertension and chronic kidney disease. Here, ATP2B4 is linked to cardiac hypertrophy.